News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
728,391 Results
Type
Article (51284)
Company Profile (312)
Press Release (676795)
Section
Business (215287)
Career Advice (3017)
Deals (37416)
Drug Delivery (98)
Drug Development (85316)
Employer Resources (184)
FDA (16914)
Job Trends (15951)
News (365715)
Policy (35583)
Tag
Academia (2829)
Africa (932)
Alliances (53530)
Alzheimer's disease (1210)
Approvals (16823)
Arizona (190)
Artificial intelligence (85)
Asia (41943)
Australia (6873)
Bankruptcy (373)
Best Places to Work (11827)
Biosimilars (70)
Biotechnology (204)
C2C Services and Suppliers (83039)
California (1923)
Canada (948)
Cancer (538)
Career advice (2521)
Cell therapy (138)
China (158)
Clinical research (66732)
Collaboration (152)
Colorado (84)
Compensation (82)
Connecticut (79)
COVID-19 (2702)
Cystic fibrosis (77)
Data (317)
Diabetes (90)
Diagnostics (6245)
Drug pricing (79)
Earnings (86048)
Employer resources (159)
Europe (91049)
Events (113096)
Executive appointments (159)
FDA (17146)
Florida (273)
Funding (156)
Gene therapy (105)
GLP-1 (590)
Government (4680)
Healthcare (19720)
Hotbed/Location (500483)
Illinois (278)
Indiana (157)
Infectious disease (2732)
Inflammatory bowel disease (102)
Interviews (553)
IPO (16746)
Job creations (4263)
Job search strategy (2112)
Kansas (97)
Layoffs (436)
Legal (8822)
Lung cancer (124)
Manufacturing (98)
Maryland (417)
Massachusetts (1591)
Medical device (13630)
Medtech (13635)
Mergers & acquisitions (20523)
Metabolic disorders (284)
Michigan (125)
Minnesota (224)
Neuroscience (1373)
New Jersey (598)
New York (606)
NextGen Class of 2024 (7013)
Non-profit (4800)
North Carolina (625)
Northern California (832)
Obesity (168)
Ohio (107)
Opinion (230)
Patents (81)
Pennsylvania (586)
People (59146)
Pharmaceutical (89)
Phase I (20583)
Phase II (29321)
Phase III (22017)
Pipeline (114)
Postmarket research (2829)
Preclinical (8791)
Press Release (70)
Rare diseases (141)
Real estate (6474)
Recruiting (71)
Regulatory (23092)
Research institute (2526)
Resumes & cover letters (494)
South America (1316)
Southern California (775)
Startups (3927)
Texas (249)
United States (8887)
Vaccines (545)
Washington State (262)
Weight loss (157)
Date
Today (124)
Last 7 days (657)
Last 30 days (2528)
Last 365 days (38582)
2024 (27243)
2023 (41479)
2022 (52732)
2021 (57400)
2020 (56250)
2019 (49306)
2018 (37409)
2017 (34544)
2016 (34356)
2015 (40167)
2014 (34155)
2013 (29373)
2012 (31498)
2011 (32166)
2010 (30450)
728,391 Results for "kinetix pharmaceuticals inc merged with amgen see amgen".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Obesity
Amgen Plans Phase III Program for Next-Gen Obesity Drug Targeting Liver and Kidney Diseases
A broad indication for MariTide could help Amgen secure Medicare coverage for the treatment following FDA approval, CEO Robert Bradway said at Wednesday’s Morgan Stanley Global Healthcare Conference.
September 5, 2024
·
2 min read
·
Tristan Manalac
Business
Stada Bags European Rights from Alvotech to Biosimilar of Amgen Blockbusters
Stada announced Tuesday it has secured European rights from Alvotech to a clinical-stage biosimilar of Amgen’s blockbuster bone drugs Prolia and Xgeva.
June 11, 2024
·
2 min read
·
Nick Paul Taylor
Job Trends
AMGEN TO PRESENT INNOVATIVE RHEUMATOLOGY RESEARCH AT EULAR 2024
Amgen (NASDAQ:AMGN) today announced the presentation of data across its diverse portfolio and pipeline at the European Alliance of Associations for Rheumatology’s (EULAR) 2024 Congress, June 12-15 in Vienna.
June 12, 2024
·
28 min read
Drug Development
Amgen Axes Development of Early-Stage Bispecific T-Cell Engager for Solid Tumors
Amgen has quietly discontinued the development of its Phase I bispecific T-cell engager AMG 794, which the company had been studying for several malignant solid tumors.
July 10, 2024
·
2 min read
·
Tristan Manalac
Drug Development
Amgen Phase III Win Positions Uplizna for Label Expansion in Rare Autoimmune Disease
Amgen’s CD19-directed antibody Uplizna in a late-stage study showed it can suppress the risk of flares by nearly 90% in patients with IgG4-related disease, the company announced Wednesday.
June 6, 2024
·
2 min read
·
Tristan Manalac
Biotech Bay
Amgen to Present at Jefferies 2024 Global Healthcare Conference
Amgen will present at Jefferies Global Healthcare Conference at 9:00 a.m. ET on Thursday, June 6, 2024.
June 3, 2024
·
1 min read
Business
AMGEN REPORTS FIRST QUARTER 2024 FINANCIAL RESULTS
Amgen (NASDAQ:AMGN) today announced financial results for the first quarter 2024.
May 2, 2024
·
42 min read
FDA
Amgen’s T-Cell Engager Wins FDA Approval for Difficult-to-Treat Lung Cancer
Bolstered by promising response data from its Phase II study, Amgen announced Thursday it got the FDA’s green light for its first-in-class bi-specific T-cell engager Imdelltra for extensive-stage small lung cancer.
May 17, 2024
·
2 min read
Job Trends
AMGEN TO PRESENT AT GOLDMAN SACHS 45TH ANNUAL GLOBAL HEALTHCARE CONFERENCE
Amgen (NASDAQ:AMGN) will present at the Goldman Sachs 45th Annual Global Healthcare Conference at 9:20 a.m. ET on Monday, June 10, 2024.
June 5, 2024
·
2 min read
FDA
Sandoz Nabs FDA Approvals for First Two Biosimilars for Amgen’s Denosumab
Sandoz’s two interchangeable biosimilars, Jubbonti and Xgeva, are poised to challenge Amgen’s blockbuster bone drug denosumab. However, no launch details were announced Tuesday due to ongoing patent litigation.
March 6, 2024
·
2 min read
·
Tristan Manalac
1 of 72,840
Next
